Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $19.33 Average PT from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned an average recommendation of “Hold” from the six ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $19.33.

Several analysts have issued reports on ENTA shares. StockNews.com lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 6th. JPMorgan Chase & Co. cut their price target on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently made changes to their positions in ENTA. Assenagon Asset Management S.A. increased its stake in shares of Enanta Pharmaceuticals by 613.6% during the third quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company’s stock valued at $7,055,000 after buying an additional 543,111 shares during the period. Jump Financial LLC increased its stake in shares of Enanta Pharmaceuticals by 41.5% during the third quarter. Jump Financial LLC now owns 56,636 shares of the biotechnology company’s stock valued at $633,000 after buying an additional 16,608 shares during the period. Clearstead Advisors LLC purchased a new position in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $57,000. Quantbot Technologies LP increased its stake in shares of Enanta Pharmaceuticals by 2,300.0% during the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,900 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $698,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Stock Up 0.9 %

NASDAQ ENTA opened at $13.44 on Friday. The company has a 50-day simple moving average of $14.84 and a two-hundred day simple moving average of $11.78. Enanta Pharmaceuticals has a 12-month low of $8.08 and a 12-month high of $37.75. The firm has a market cap of $284.39 million, a price-to-earnings ratio of -2.05 and a beta of 0.47.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The business had revenue of $18.00 million for the quarter, compared to analysts’ expectations of $22.74 million. Equities analysts expect that Enanta Pharmaceuticals will post -4.9 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.